Antiparasitic drugs are a group of medications used in the management and treatment of infections by parasites, including protozoa, helminths, and ectoparasites. Parasites are minuscule creatures that live on or inside plants, humans, and animals. They are the cause of parasitic illnesses.
Antiparasitic drugs include,
Antiprotozoal agents: Antimalarials Agents, Antibabesial Agents, Antiamoebic Agents, Others (Trypanocidal Agents, Antileishmanial Agents, etc.). Anthelmintics: Anticestodal Drugs, Antitrematodal Drugs, Antinematodal Drugs. Ectoparasiticide: Antiscabietic Agents, Pediculicides
Antiparasitic drugs market is estimated to be valued at US$ 22.22 Billion in 2022 and is expected to exhibit a CAGR of 5.6 % over the forecast period (2022-2030)
Figure 1. Global Antiparasitic Drugs Market Value (US$ Bn), By Region, 2022
Increasing product launches, agreements or partnerships, and investment by market players are some of the factors responsible for growth of the global antiparasitic drugs market over the forecast period.
For instance, in January 2019, Corteva Agriscience, the agriculture division of DowDuPont, and Stoller, a global company focused on plant nutrition foliar and biological solutions, announced a commercial agreement for the exclusive distribution of Rizotec, a bionematicide that act against nematode caused parasitic infections in sugarcane crops.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 22.22 Bn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 5.6 % | 2030 Value Projection: | US$ 34.44 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Merck KGaA, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd, Cipla Limited, Cadila Pharmaceuticals, Watson International Limited, Vivaldis, Glenmark Pharmaceuticals Limited, Viatris Inc., Novartis AG, AdvaCare Pharma, Lupin, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2. Global Antiparasitic Drugs Market Share (%), By Product Type, 2022
Increasing product launches and approvals by market players are expected to drive the antiparasitic drugs market growth over the forecast period.
For instance, in August 2021, ParaPRO, a specialty pharmaceutical company focused on innovative anti-parasitic treatments, announced the launch of Natroba (spinosad) Topical Suspension, 0.9 %, for scabies treatment. The supplemental New Drug Application (sNDA) for Natroba, a focused topical treatment for scabies infestations in adult and pediatric patients four years of age and older, was approved by the US Food and Drug Administration (FDA) in April 2021
Global Antiparasitic Drugs Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 a pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 575,887,049 cases of coronavirus disease (COVID-19) were reported till 2nd August, 2022, across the globe.
Supply chain and manufacturing activities in India, Italy, Spain, the U.K., and the U.S. have been disrupted due to lockdowns implemented by governments, while countries such as Saudi Arabia, the U.A.E., Egypt, and others are facing problems with regards to transportation of raw materials, chemicals as well as finished products.
Manufacturing sites, which are based in worst hit countries have been affected severely due to severe shortage of medical resources and raw materials. This has led to global supply disruption.
Although COVID-19 infection is incurable, numerous attempts have been made to repurpose existing therapeutic agents, particularly antiparasitic ones. According to an article published in Future Virology Journal, a medical journal published by future medicine in March 2022, the anthelmintic drug albendazole seems to have a protective effect in COVID-19 patients with hydatid cysts caused by the tapeworm Echinococcus granolusus. Additionally, ivermectin seems to work against COVID-19 and appears to do so via inhibiting the viral protease.
However, ivermectin is still not approved by the U.S. Food and Drug Administration (FDA) for the prevention or treatment of COVID-19 in humans or animals, despite studies showing the paradoxical effect of anti-parasitic medications on COVID-19. Further research with a large population in different geographic areas therefore appears to be necessary.
The use of antiparasitic drugs during the pandemic to treat the COVID-19 infection and the ongoing research for the same is expected to increase demand for antiparasitic agents.
Global Antiparasitic Drugs Market Restraint
Rising cost of the antiparasitic drugs is expected to hinder the market growth over the forecast period. For instance, according to the American Journal of Tropical Medicine and Hygiene, 2021, the increasing price of pharmaceuticals in the U.S., which are used to treat three soil-transmitted helminth infections, hookworm, roundworm (ascariasis), and whipworm (trichuriasis) has led to increase in overall treatment for patients with Medicaid or private insurance.
Key Players
Major players operating in the global antiparasitic drugs market include Merck KGaA, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd, Cipla Limited, Cadila Pharmaceuticals, Watson International Limited, Vivaldis, Glenmark Pharmaceuticals Limited, Viatris Inc., Novartis AG, AdvaCare Pharma, Lupin, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma
Antiparasitic drugs treat parasitic infections. These infections result from parasites, which are tiny organisms that live on or inside people and animals. There are various antiparasitic drugs, each drug targets a specific parasite.
Antiparasitic drugs treat several kinds of infections that result from a thousand types of parasites. Three main types of parasites which can make people sick are, Ectoparasites, Helminths, and Protozoas, which are treated with antiparasitic drugs such as anticestodal drugs, antitrematodal drugs, antinematodal drugs, antimalarials agents, antibabesial agents, antiamoebic agents, trypanocidal agents, antileishmanial agents, antiscabietic agents, and pediculicides.
Market Dynamics
Governments of various countries, non-profit organizations, and some market players such as Novartis, etc. are involved in initiatives and campaigns to increase the widespread use of antiparasitic drugs and improve the treatment of tropical diseases including parasitic illness such as malaria, leishmaniasis, Chagas disease, etc. This would in turn increase demand for antiparasitic drugs and hence fuel growth of the global antiparasitic drugs market over the forecast period.
For instance, in October 2021, The President's Malaria Initiative (PMI) of the U. S. launched a new five-year strategy, ‘End Malaria Faster’, with the goal of eliminating malaria within a generation, contributing to global targets of saving more than 4 million lives and averting 1 billion cases by 2025. The five-year PMI strategy seeks to reduce health inequities, improve disease surveillance, and continue to save lives.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients